🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Manisha H. Shah

The Ohio State University Wexner Medical Center

ORCID: 0000-0002-6453-2044

Also affiliated with Pakistan Institute of Medical Sciences, The Ohio State University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)”.

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

Journal of Clinical Oncology(2022)10.1200/jco.22.01013
N/A
4.9DataRank · unranked
297 citations

Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre +14 more

Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study

˜The œLancet. Gastroenterology & hepatology(2022)10.1016/s2468-1253(21)00382-4
N/A
2.2DataRank · unranked
73 citations

Philippe A. Cassier, Marwan Fakih, Steven Kao, Dorte Nielsen, Antoîne Italiano +17 more

A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4004
N/A
0.464DataRank · unranked
21 citations

Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre +15 more

Data from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

(2023)10.1158/1078-0432.c.6533090
N/A
0DataRank · unranked
0 citations

Brooke Benner, Lai Wei, Vineeth Sukrithan, Ashima Goyal, Ye Zhou +17 more

Data from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

(2023)10.1158/1078-0432.c.6533090.v1
N/A
0DataRank · unranked
0 citations

Brooke Benner, Lai Wei, Vineeth Sukrithan, Ashima Goyal, Ye Zhou +17 more

Telomere-lengthening germline variants predispose to a syndromic papillary thyroid cancer subtype

The American Journal of Human Genetics(2024)10.1016/j.ajhg.2024.04.006
N/A
0DataRank · unranked
22 citations

Anna M. Nicosia, Sandya Liyanarachchi, Sheila Iyer, Manisha H. Shah, Matthew D. Ringel +3 more

A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1552
N/A
0DataRank · unranked
36 citations

Brooke Benner, Lai Wei, Vineeth Sukrithan, Ashima Goyal, Ye Zhou +17 more

Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad096
N/A
0DataRank · unranked
9 citations

Thomas A. Hope, Emily B Bergsland, Lisa Bodei, David Bushnell, Jennifer A. Chan +63 more